Ex vivo dual gene therapy using human adipocytes secreting anti-HER2 antibody on HER2-positive xenograft tumor models

被引：0
|
作者：
Ryotaro Teranaka
Hiroshi Fujimoto
Takahito Masuda
Masayuki Kuroda
Yasuyuki Aoyagi
Takeshi Nagashima
Mamoru Takada
Junta Sakakibara
Hideyuki Yamada
Hiroto Yamamoto
Yoshitaka Kubota
Masayuki Ohtsuka
机构：
[1] Chiba University Graduate School of Medicine,Department of General Surgery
[2] Chiba University Hospital,Center for Advanced Medicine
[3] CellGenTech,Department of Plastic, Reconstructive, and Aesthetic Surgery
[4] Inc.,undefined
[5] Chiba University Graduate School of Medicine,undefined
来源：
Breast Cancer | 2023年 / 30卷
关键词：
Breast cancer; Adipocytes; Gene therapy; Human epidermal growth factor receptor 2; Molecular target therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1018 / 1027
页数：9
相关论文
共 50 条
  • [1] Ex vivo dual gene therapy using human adipocytes secreting anti-HER2 antibody on HER2-positive xenograft tumor models
    Teranaka, Ryotaro
    Fujimoto, Hiroshi
    Masuda, Takahito
    Kuroda, Masayuki
    Aoyagi, Yasuyuki
    Nagashima, Takeshi
    Takada, Mamoru
    Sakakibara, Junta
    Yamada, Hideyuki
    Yamamoto, Hiroto
    Kubota, Yoshitaka
    Ohtsuka, Masayuki
    BREAST CANCER, 2023, 30 (06) : 1018 - 1027
  • [2] Anti-HER2 antibody therapy using gene-transduced adipocytes for HER2-positive breast cancer
    Takahito Masuda
    Hiroshi Fujimoto
    Ryotaro Teranaka
    Masayuki Kuroda
    Yasuyuki Aoyagi
    Takeshi Nagashima
    Takafumi Sangai
    Mamoru Takada
    Ayako Nakagawa
    Yoshitaka Kubota
    Koutaro Yokote
    Masayuki Ohtsuka
    Breast Cancer Research and Treatment, 2020, 180 : 625 - 634
  • [3] Anti-HER2 antibody therapy using gene-transduced adipocytes for HER2-positive breast cancer
    Masuda, Takahito
    Fujimoto, Hiroshi
    Teranaka, Ryotaro
    Kuroda, Masayuki
    Aoyagi, Yasuyuki
    Nagashima, Takeshi
    Sangai, Takafumi
    Takada, Mamoru
    Nakagawa, Ayako
    Kubota, Yoshitaka
    Yokote, Koutaro
    Ohtsuka, Masayuki
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 180 (03) : 625 - 634
  • [4] A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells
    Shengnan Yu
    Jing Zhang
    Yongxiang Yan
    Xudong Yao
    Lijuan Fang
    Hui Xiong
    Yang Liu
    Qian Chu
    Pengfei Zhou
    Kongming Wu
    Journal of Experimental & Clinical Cancer Research, 38
  • [5] A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells
    Yu, Shengnan
    Zhang, Jing
    Yan, Yongxiang
    Yao, Xudong
    Fang, Lijuan
    Xiong, Hui
    Liu, Yang
    Chu, Qian
    Zhou, Pengfei
    Wu, Kongming
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2019, 38 (01)
  • [6] Margetuximab Anti-HER2 monoclonal antibody Treatment of metastatic HER2-positive breast cancer Treatment of HER2-positive gastric or gastroeso-phageal junction cancer
    Hanna, K. S.
    DRUGS OF THE FUTURE, 2021, 46 (03) : 191 - 195
  • [7] De novo resistance biomarkers to anti-HER2 therapies in HER2-positive breast cancer
    Madrid-Paredes, Adela
    Canadas-Garre, Marisa
    Sanchez-Pozo, Antonio
    Angel Calleja-Hernandez, Miguel
    PHARMACOGENOMICS, 2015, 16 (12) : 1411 - 1426
  • [8] NeuVax™ Anti-HER2/NEU/erbB-2 vaccine, Treatment of HER2-positive cancers
    Davies, S.
    DRUGS OF THE FUTURE, 2009, 34 (09) : 717 - 719
  • [9] RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer
    Sanz-Moreno, Adrian
    Palomeras, Sonia
    Pedersen, Kim
    Morancho, Beatriz
    Pascual, Tomas
    Galvan, Patricia
    Benitez, Sandra
    Gomez-Miragaya, Jorge
    Ciscar, Marina
    Jimenez, Maria
    Pernas, Sonia
    Petit, Anna
    Soler-Monso, Maria Teresa
    Vinas, Gemma
    Alsaleem, Mansour
    Rakha, Emad A.
    Green, Andrew R.
    Santamaria, Patricia G.
    Mulder, Celine
    Lemeer, Simone
    Arribas, Joaquin
    Prat, Aleix
    Puig, Teresa
    Gonzalez-Suarez, Eva
    BREAST CANCER RESEARCH, 2021, 23 (01)
  • [10] RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer
    Adrián Sanz-Moreno
    Sonia Palomeras
    Kim Pedersen
    Beatriz Morancho
    Tomas Pascual
    Patricia Galván
    Sandra Benítez
    Jorge Gomez-Miragaya
    Marina Ciscar
    Maria Jimenez
    Sonia Pernas
    Anna Petit
    María Teresa Soler-Monsó
    Gemma Viñas
    Mansour Alsaleem
    Emad A. Rakha
    Andrew R. Green
    Patricia G. Santamaria
    Celine Mulder
    Simone Lemeer
    Joaquin Arribas
    Aleix Prat
    Teresa Puig
    Eva Gonzalez-Suarez
    Breast Cancer Research, 23
12345